Future advancements, including novel tracers targeting specific molecular pathways like HER2 and ER, hybrid imaging technologies such as PET/MRI, and radionuclide-based treatments, promise even greater precision and personalization in breast cancer care. This evidence concerns the gene ERBB2 and breast cancer.